Nomeco A/S

Der har i lighed med regnskabsåret 2021/22 ikke været væsentlige engangsindtægter i regnskabsåret.
Der ses en positiv udviklingen i årets resultat som dels kan henføres til markedsvækst samt stigende markedsandel i apoteksdivisionen og dels en fortsat positiv udvikling i HCL forretningen efter indflytningen i det nye pre-wholesale lager i Køge. Årets realiseret tal overgår således forventningerne kommunikeret i årsrapporten for 2021/22.
Det gennemsnitlige antal fuldtidsbeskæftigede udgjorde 665 medarbejdere i 2022/23 (2021/22: 680).
Balancesummen udgjorde 4.013.660 t.kr. pr. 31. januar 2023 (31. januar 2022: 3.792.098 t.kr.), og egenkapitalen 703.504 t.kr. (31. januar 2022: 672.069 t.kr.).
Markedet for lægemidler til apotekssektoren steg med 8,8 % i regnskabsåret, hvilket er højere end forventet.
Efter flere år der har været påvirket af COVID-19-krisen har Apoteksdivisionen igen fuld fokus på markedsandele, effektivisering og optimering. Udviklingen i sektoren de seneste år efter modernisering af apotekerloven og den deraf afledte stigning i antallet af receptekspederende apoteksenheder stillinger store krav til virksomhedens processer. Markedsvækst samt stigende markedsandele i regnskabsåret har påvirket Apoteksdivisionen positivt. Resultatet i apoteksdivisionen er tilfredsstillende.
Udviklingen i HealthCare Logistics' leverandørrettede pre-wholesale og service aktiviteter, der de senere år, har været præget af indflytningen i det nye varelager i Køge, har været positiv. Efterspørgsel samt forbedrede og optimerede processer på det nye varelager betyder, at resultatet for pre-wholesale divisionen er tilfredsstillende for regnskabsåret 2022/23.
Resultatet i dattervirksomheden Specific Pharma A/S er påvirket af øget eksport, samt salg til det danske marked, hvor der igen ses en efterspørgsel efter medicinal produkter herunder ikke registrerede specialiteter. Årets resultat i dattervirksomheden er under niveau for det forventede., As in the financial year 2021/22, the financial statements reflect no one-off income.
The result for the year is positively developing, which can partly be attributed to market growth and increasing market share in the pharmacy division and partly to a continued positive development in the HCL business after moving into the new pre-wholesale warehouse in Køge. The realised figure for the year thus exceeds the expectations communicated in the annual report for 2021/22.
In 2022/23, the average number of employees was 665 full-time employees (2021/22: 680).
The balance sheet total amounted to DKK 4,013,660 thousand at 31 January 2023 (31 January 2022: DKK 3,792,098 thousand) and equity totalled DKK 703,504 thousand (31 January 2022: DKK 672,069 thousand).
The pharmaceuticals market for the pharmacy sector increased by 8.8% in the financial year, which is higher than expected.
After several years affected by the COVID-19 crisis, the pharmacy division once again has full focus on market shares, efficiency and optimization. Developments in the sector in recent years following the modernization of the pharmacies act and the consequent increase in the number of prescription-serving pharmacies place high demands on the company's processes. Market growth and increasing market shares during the financial year have had a positive impact on the pharmacy division. The result in the pharmacy division is considered satisfactory.
The development in HealthCare Logistics' supplier-oriented pre-wholesale and service activities, which in recent years have been characterized by the move into the new warehouse in Køge, has been positive. Demand as well as improved and optimized processes in the new warehouse means that the result for the pre-wholesale division is considered satisfactory for the financial year 2022/23.
The result of the subsidiary Specific Pharma A/S is affected by increased exports, as well as sales to the Danish market, where there is again a demand for pharmaceutical products, including unregistered specialties. The profit for the year in the subsidiary is below the expectations.